Results 61 to 70 of about 8,704 (178)

Eplerenone-Mediated Aldosterone Blockade Prevents Renal Fibrosis by Reducing Renal Inflammation, Interstitial Cell Proliferation and Oxidative Stress

Kidney & Blood Pressure Research, 2013
Background/Aims: Prolonged elevation of serum aldosterone leads to renal fibrosis. Inflammation also plays a role in the pathogenesis of renal disease.
Hui Chen, Feng Sun, Xiaoshi Zhong, Yuebin Shao, Ashio Yoshimura, Yan Liu   +5 more
doaj   +1 more source

Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice

International Journal of Hypertension, 2019
Eplerenone, a mineralocorticoid receptor antagonist (MRA), is available in Japan, but details of its use in clinical settings have not been thoroughly investigated.
Shoko Takahashi, Yoichi Ii, Yuji Yamamoto, Aya Ikeda, Yoko Fujimoto   +4 more
doaj   +1 more source

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Scientific Reports, 2017
Aldosterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited by hyperkalemia, especially when associated with RAS inhibitors.
Clarice K. Fujihara, M. C. Kowala, M. D. Breyer, Claudia R. Sena, Mariliza V. Rodrigues, Simone C. A. Arias, Camilla Fanelli, Denise M. Malheiros, P. K. Jadhav, Chahrzad Montrose-Rafizadeh, Jose E. Krieger, Roberto Zatz   +11 more
doaj   +1 more source

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

Orphanet Journal of Rare Diseases, 2017
Background Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was ...
Subha V. Raman, Kan N. Hor, Wojciech Mazur, Xin He, John T. Kissel, Suzanne Smart, Beth McCarthy, Sharon L. Roble, Linda H. Cripe   +8 more
doaj   +1 more source

New Clinical Aspects of Eplerenone Use in Clinical Practice

Рациональная фармакотерапия в кардиологии, 2018
The problem of the discrepancy between convincing evidences of the effectiveness of the use of mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction and insufficiently frequent their use in ...
S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina   +3 more
doaj   +1 more source

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

Health Technology Assessment, 2010
Background: Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone. Recent clinical guidelines recommend eplerenone after an acute myocardial infarction (MI) for patients with symptoms and/or ...
C McKenna, J Burch, S Suekarran, S Walker, A Bakhai, K Witte, M Harden, K Wright, N Woolacott, P Lorgelly, L Fenwick, S Palmer   +11 more
doaj   +1 more source

Eplerenone as a novel treatment for persistent subretinal fluid following retinal detachment surgery

American Journal of Ophthalmology Case Reports, 2018
Purpose: To describe the clinical course of a patient with persistent subretinal fluid (SRF) after primary scleral buckle surgery for a rhegmatogenous retinal detachment (RRD) repair who was subsequently treated with oral eplerenone for resolution of SRF.
Arezu Haghighi, Jiun Do, Hossein Ameri
doaj   +1 more source

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Vascular Health and Risk Management, 2018
Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department ...
Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E   +5 more
doaj  

Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy

Frontiers in Pharmacology
BackgroundThe renin-angiotensin-aldosterone system (RAAS) members, especially Ang II and aldosterone, play key roles in the pathogenesis of diabetic cardiomyopathy (DCM).
Lin Xie, Dejin Zang, Jianmin Yang, Fei Xue, Wenhai Sui, Yun Zhang, Yun Zhang   +6 more
doaj   +1 more source

Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy

Scientific Reports
Preeclampsia is a severe pregnancy complication associated with substantial injury to systemic vasculature, major organs, and the feto-placental unit, with an approximate mortality rate of 76,000 pregnant women and 500,000 babies each year.
Natalie K. Binder, Natasha de Alwis, Sally Beard, Bianca R. Fato, Anjali Garg, Lydia Baird, Morag J. Young, Natalie J. Hannan   +7 more
doaj   +1 more source